Literature DB >> 9855368

No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia.

H Arai1, T Satoh-Nakagawa, M Higuchi, Y Morikawa, M Miura, H Kawakami, H Seki, S Takase, H Sasaki.   

Abstract

Tau protein levels in cerebrospinal fluid (CSF-tau) were determined in 29 patients with old cerebrovascular disease (CVD, 21 demented and eight non-demented), 69 patients with Alzheimer's disease (AD) and 17 age-matched normal controls. The CSF-tau level in the vascular dementia (VD) group (24.0 +/- 17.0 pg/ml) was significantly lower (P < 0.0001) than that in the AD group (90.0 +/- 45.3 pg/ml), but not significantly different from that in the non-demented patients with CVD (18.1 +/- 10.2 pg/ml) or controls (20.3 +/- 13.0 pg/ml). Among the VD patients, 1/21 exceeded a cut-off value (mean +/- 2 SD of controls), whereas 8/69 of the AD patients had CSF-tau levels below this value. These findings suggest that VD constitutes a group of dementias that can be separated from AD by normal CSF-tau levels. CSF-tau determinations in combination with other clinical findings may provide another diagnostic aid in the differential diagnosis between VD and AD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855368     DOI: 10.1016/s0304-3940(98)00781-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

Review 1.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

2.  Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease.

Authors:  Sudad Saman; WonHee Kim; Mario Raya; Yvonne Visnick; Suhad Miro; Sarmad Saman; Bruce Jackson; Ann C McKee; Victor E Alvarez; Norman C Y Lee; Garth F Hall
Journal:  J Biol Chem       Date:  2011-11-04       Impact factor: 5.157

3.  CSF Biomarkers Profile in CADASIL-A Model of Pure Vascular Dementia: Usefulness in Differential Diagnosis in the Dementia Disorder.

Authors:  Patrizia Formichi; Lucilla Parnetti; Elena Radi; Gabriele Cevenini; Maria Teresa Dotti; Antonio Federico
Journal:  Int J Alzheimers Dis       Date:  2010-08-18

Review 4.  Biomarkers of Alzheimer's disease.

Authors:  Rebecca Craig-Schapiro; Anne M Fagan; David M Holtzman
Journal:  Neurobiol Dis       Date:  2008-10-28       Impact factor: 5.996

Review 5.  Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

Authors:  Catherine Randall; Lisa Mosconi; Mony de Leon; Lidia Glodzik
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

Review 6.  CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.

Authors:  K Blennow; E Vanmechelen; H Hampel
Journal:  Mol Neurobiol       Date:  2001 Aug-Dec       Impact factor: 5.682

7.  Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases.

Authors:  Shieh-Yueh Yang; Ming-Jang Chiu; Ta-Fu Chen; Chin-Hsien Lin; Jiann-Shing Jeng; Sung-Chun Tang; Yen-Fu Lee; Che-Chuan Yang; Bing-Hsien Liu; Hsin-Hsien Chen; Chau-Chung Wu
Journal:  Sci Rep       Date:  2017-08-24       Impact factor: 4.379

8.  CSF tau protein and FDG PET in patients with aging-associated cognitive decline and Alzheimer's disease.

Authors:  Aoife Hunt; Peter Schönknecht; Markus Henze; Pablo Toro; Uwe Haberkorn; Johannes Schröder
Journal:  Neuropsychiatr Dis Treat       Date:  2006-06       Impact factor: 2.570

Review 9.  Exosomes in Pathogenesis, Diagnosis, and Treatment of Alzheimer's Disease.

Authors:  Liqun Jiang; Huijie Dong; Hua Cao; Xiaofei Ji; Siyu Luan; Jing Liu
Journal:  Med Sci Monit       Date:  2019-05-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.